Purple Biotech Ltd.
NASDAQ:PPBT
2.97 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | -0.91 | -0.32 | 1 | 1 | 1 | 0.901 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.196 | 0.201 | 0.231 | 0.235 | 0 | 0 | 0.004 | 0.002 | 0.001 | 0 | 0 | 0 |
| Gross Profit
| -0.196 | -1.111 | -0.551 | 0.765 | 1 | 1 | 0.897 | -0.002 | -0.001 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 1.221 | 1.722 | 0.765 | 1 | 1 | 0.996 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 17.034 | 16.32 | 11.827 | 7.488 | 2.674 | 5.268 | 4.64 | 4.18 | 2.56 | 3.192 | 0.109 | 0 |
| General & Administrative Expenses
| 0 | 5.962 | 5.821 | 6.071 | 6.078 | 4.452 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 | 0.001 |
| Selling & Marketing Expenses
| 0 | 0.321 | 0.286 | 0.235 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.041 | 6.283 | 6.107 | 6.306 | 6.078 | 4.452 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 | 0.001 |
| Other Expenses
| -44.542 | 0 | 0 | -15.655 | -0.216 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| -22.467 | 22.603 | 17.934 | 13.794 | 8.752 | 8.826 | 12.061 | 7.183 | 4.069 | 5.181 | 1.17 | 0.001 |
| Operating Income
| 22.271 | -22.603 | -17.934 | 12.612 | -7.156 | -7.826 | -12.246 | -7.183 | -4.069 | -5.181 | -2.553 | -0.001 |
| Operating Income Ratio
| 0 | 24.838 | 56.044 | 12.612 | -7.156 | -7.826 | -13.592 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -42.248 | 0.843 | 0.108 | -40.686 | 1.263 | 2.74 | -1.049 | -5.074 | -0.079 | -0.071 | -1.383 | -0 |
| Income Before Tax
| -19.977 | -21.76 | -17.826 | -28.074 | -5.893 | -5.569 | -13.008 | -12.125 | -4.202 | -5.252 | -2.628 | -0.001 |
| Income Before Tax Ratio
| 0 | 23.912 | 55.706 | -28.074 | -5.893 | -5.569 | -14.437 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.097 | -0.935 | 0.637 | -15.669 | 0.216 | -2.626 | 0.026 | 4.942 | 0.133 | 0.05 | 0.027 | 0 |
| Net Income
| -19.88 | -20.825 | -18.463 | -12.405 | -6.109 | -5.2 | -12.272 | -12.125 | -4.202 | -5.252 | -2.628 | -0.001 |
| Net Income Ratio
| 0 | 22.885 | 57.697 | -12.405 | -6.109 | -5.2 | -13.62 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted
| -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| EBITDA
| -22.225 | -21.433 | -17.383 | -27.96 | -7.638 | -7.726 | -11.929 | -7.043 | -4.198 | -5.231 | -1.197 | 0 |
| EBITDA Ratio
| 0 | 23.553 | 54.322 | -27.96 | -7.638 | -7.726 | -13.24 | 0 | 0 | 0 | 0 | 0 |